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A COMPARATIVE ANALYSIS OF THE FINANCING, PRICING
AND REIMBURSEMENT SYSTEMS FOR PRESCRIPTION DRUGS
IN THE NORDIC COUNTRIES
Kristensen FKO, Sverre JM, Holm LB
PharmEcon AS, Asker, Norway
OBJECTIVES: To elicit similarities and differences in the poli-
cies and practices for ﬁnancing, pricing and reimbursing pre-
scription drugs in the often perceived similar Nordic countries
of Denmark (D), Finland (F), Norway (N) and Sweden (S).
METHODS: A review of the four countries’ authorities’ stated
policies and practices on the matter were performed through a
search of the literature and of the respective authorities’ home-
pages. The information was validated through interviews with
key personnel of the reimbursement agencies in each country,
and the ﬁnal study reports for the respective countries were
reviewed by the same persons. RESULTS: All countries have a
national health care system ﬁnanced by taxation. There are dif-
ferences in the reliance upon patient co-payment (N 13%, others
22–37%) and whether ﬁnancing is a county (S) or national
(others) responsibility. All have regulated prices for reimbursed
drugs; based either upon international comparisons (N, D) or
country-speciﬁc decisions (S, F). The criteria used for deciding to
reimburse a drug vary between the countries, and reimbursement
is practiced differently in several other dimensions: mandatory
requirement for pharmacoeconomic analysis (F, N, S), the 
existence of patient-speciﬁc reimbursement systems (D, F, N),
product- (S) or indication-based (others) reimbursement, use of
graded (F), conditional (N, S) or temporary (S) reimbursement,
use of reimbursement contracts (N), and different processes for
handling disagreement about decisions. CONCLUSION: The
Nordic countries all have a national health care system ﬁnanced
by taxation and encompassing prescription drugs, but differ in
a number of other dimensions with respect to ﬁnancing, pricing
and reimbursing such drugs.
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A SYSTEMATIC REVIEW OF THE EUROPEAN
PHARMACEUTICAL MARKET AND THE IMPACT OF
EUROPEAN UNION REGULATION AND JURISDICTION
Van Ginneken EJ, Schreyögg J, Gericke CA, Busse R
Berlin University of Technology, Berlin, Germany
OBJECTIVES: To examine the impact of the increasing role 
of the European Union (EU) on the European pharmaceutical
market, focusing on industry and national policies. To give a sys-
tematic overview of the current state of the European pharma-
ceutical market as a whole. METHODS: Systematic literature
review for the years 1965–2005, including “grey” sources of
information, online databases, European Commission docu-
ments and European Court of Justice rulings, relevant journals
and systematically tracing back relevant references. RESULTS:
The EU attempts to liberalise the pharmaceutical market and the
realisation of a Single European Market (SEM) came to a stand-
still, after some considerable achievements (e.g. marketing
authorisation). Instead, the EU seems to concentrate on coor-
dination of results through the adoption of the so-called G10
recommendations. EU Member States successfully—and inten-
tionally—kept control on the issues of pricing, reimbursement,
pharmacies and prescribing. Over the last 25 years they adapted
increasingly convergent measures to cope with rising pharma-
ceutical expenditures, without long-lasting cost containment
effects. However, recent European case law might prove to have
far reaching consequences on the provision of medicines. The
European pharmaceutical industry—although proﬁtable—is
underperforming compared to the USA, which is blamed on
restrictive regulatory frameworks in the Member States. CON-
CLUSIONS: The future of the actors in the European pharma-
ceutical market is not clear. Will it bring more European
inﬂuence or a strengthening of national inﬂuence? In the short
term, major change towards a SEM seems unlikely, but in the
longer term European history showed that major change is pos-
sible. It seems clear that much depends on the attitude of
Member States towards the new approach and the interpretation
and inﬂuence of European case law. For the European industry,
adoption and implementation of G10 recommendations is of
great importance for future competition with US-based 
companies.
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USING AN ITALIAN POPULATION DATABASE TO PROFILE
PREVALENCE AND COSTS OF CHRONIC CONDITIONS
Yuen EJ, Maio V, Louis DZ, Rabinowitz C, Robeson M, Smith KD
Jefferson Medical College,Thomas Jefferson University, Philadelphia,
PA, USA
OBJECTIVE: Individuals with chronic medical illness may have
multiple health problems, and are often costly and difﬁcult to
manage. This study identiﬁes those with highly prevalent chronic
conditions and assesses related health service use and costs in the
population of Emilia Romagna (RER), a large northern Italian
region. METHODS: Pharmaceutical, hospital, and demographic
data from 2000 and 2001 have been assembled for the entire
population of RER (4 million). Pharmaceutical and hospital
tariffs were a proxy for costs. Pharmacy and hospital records
were used to identify individual morbidity. Data included demo-
graphic and geographic information, encounter dates, diagno-
sis/procedure codes, pharmaceutical information, and health
care costs. Individuals were classiﬁed as having a chronic condi-
tion in 2000, and we examined pharmacy and hospital use/costs
in 2001. Descriptive analyses compared mean and total costs, as
well as proportions within the population. RESULTS: We iden-
tiﬁed ﬁve highly prevalent chronic conditions: cardiovascular dis-
eases (N = 824,190, 20.8% of the population); rheumatologic
conditions (N = 172,402, 4.4%); gastric acid disorders (N =
142,191, 3.6%); chronic respiratory illnesses (N = 154,601,
3.9%); and psychiatric disorders (94,140, 2.4%). 27.3% of the
population had one or more of these ﬁve chronic conditions, and
these individuals accounted for 72.8% of the pharmacy costs and
58.9% of the hospital costs in the following year. For persons
with these ﬁve conditions, we also described use and costs by age
and gender, residence, and income. CONCLUSIONS: Interest-
ingly, one-fourth of the population with selected chronic condi-
tions accounted for large proportions of cost and use of health
services. The ability to identify those with chronic conditions
would help planners and governmental agencies to address
health care needs, increase quality of care, avoid unnecessary
hospitalizations, and save costs. These types of data can be used
to estimate health care ﬁnancing and risk adjustment models,
and proﬁle speciﬁc clinical, demographic or geographic 
sub-groups.
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ADHERENCE INDEX OF PERFORMANCE—A NEW METHOD
AND TOOL FOR ONGOING EVALUATION OF MEDICATION
ADHERENCE IMPROVEMENT INITIATIVES
Day D
Pﬁzer, New York, NY, USA
OBJECTIVES: To develop a standardized means for measuring
the impact of medication adherence improvement initiatives in
disparate pharmacy claims databases over sequentially overlap-
ping periods of time. METHODS: The Adherence Index of 
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Performance (AIP) tool was developed by combining Microsoft
Visual Basic 6.0 with a series of SQL statements that transform
pharmacy databases into a standardized format. Once stan-
dardized, a second series of SQL statements were applied to
allow tracking of prescription activity levels compared to
expected activity levels over sequentially overlapping periods of
time. RESULTS: AIP detects trends in medication adherence rel-
atively early after the initiation of adherence improvement activ-
ities. This represents a signiﬁcant improvement over traditional
methods for studying the impact of patient interventions on med-
ication adherence and provides opportunities for early modiﬁ-
cation of adherence improvement activities that do not achieve
their intended goals. CONCLUSIONS: AIP allows targeting of
speciﬁc patients for adherence interventions based on persis-
tence. Through use of dynamic ﬁlters, AIP can also identify
health care providers and institutions where adherence improve-
ment initiatives are most needed. Additionally, user-deﬁned ther-
apeutic groupings and intent to treat categorization allows AIP
to generate accurate medication adherence information when
patients are initiated on one medication in a therapeutic class but
ultimately maintained on another medication within a deﬁned
therapeutic class. The Adherence Index of Performance provides
a unique means for monitoring the impact of medication adher-
ence improvement initiatives through analysis of pharmacy
claims databases. AIP converts claims databases into a stan-
dardized format upon which a series of pre-deﬁned analytical
processes can be applied. This allows tracking of prescription
activity levels for both new and continuing patients compared to
expected activity levels over sequentially overlapping periods of
time. It has been successfully used by a number of health care
providers to monitor the impact of adherence interventions on
patients’ medication-taking behaviors.
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PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT)
COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL
(TH) COST USING THE MINIMUM BASIC DATA SET (MBDS)
Van Wilder P,Verplanken P, Bormans V
S.M.A.R.T, Zaventem, Belgium
OBJECTIVES: Estimates of ﬁxed funding budgets can only be
accurate if all pathology related insurance costs are considered.
In this work we analysed the predictive value of LOS and PT
cost on TH insurance cost as surrogates for total budget esti-
mation. These predictors may already be available prior to the
various other cost elements and act as management indicators.
METHODS: Belgian hospitals register admission data in MBDS;
the Health Authorities make annual data freely available via 
the web (https://tct.fgov.be/etct/) on insurance costs (medicines,
medical or surgical procedures, laboratory requests, others)
relating to hospital stays per All Patients Reﬁned Diagnosis
Related Groups (APRDRG) and per stay severity. Data from 
the year 2000 were analyzed in SPSSWIN12.0 using multiple
forward stepwise linear regression. For each variable the median
value was used. Data transformations were used if appropriate.
RESULTS: On APRDRG-level median TH-cost was signiﬁcantly
correlated to HS-cost (r = 0.858, p < 0.0001) and PT-cost (r =
0.708, p < 0.0001). Median TH-cost increased with stay sever-
ity (minor 1728 Euro, extreme 8984 Euro).The linear regression
model considered the inclusion of the factors LOS, PT-cost, mean
patient age and stay severity on TH-cost; the selected model had
an adjusted R2 = 0.767 and included LOS (change in R2 = 0.691),
PT-cost (change in R2 = 0.038) and minor to moderate severity
(all factors with p < 0.001).The model ﬁtted the data of >340
APRDRGs; liver transplantation, major cardio-vascular surgery,
threatened abortion and alcohol abuse may beneﬁt from speciﬁc
modeling. CONCLUSIONS: LOS and pharmaceutical treatment
cost allow explaining >70% of the variance of the total hospi-
tal-cost as measured in real life MBDS-data; these predictors may
be useful as budget management indicators for a majority of
APRDRGs before detailed ﬁnancial data become available.
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ECONOMIC EVALUATION OF NEW TECHNOLOGIES IN THE
HOSPITAL SETTING: THE EXPERIENCE OF THE AZIENDA
OSPEDALIERA DI VERONA, ITALY
Marini P, Filippi C, Ghirlanda G, Perilli V, Scroccaro G
Azienda Ospedaliera di Verona,Verona, Italy, Italy
OBJECTIVE: To evaluate the opportunity of introducing new
technologies in the medical device formulary of the Azienda
Ospedaliera di Verona. As an example, kyphoplasty evaluation
is described. METHODS: In order to control the medical devices
purchasing process, at the Azienda Ospedaliera di Verona (two
hospitals, one teaching and one general, accounting for about
2000 beds) a multidisciplinary Medical Devices Formulary Com-
mittee (MDFC) was established. The tasks of the MDFC are: to
evaluate the introduction of new medical devices in the hospital
formulary; to monitor the appropriate use of medical devices
after their introduction. The committee approves the introduc-
tion into the formulary of new medical devices with innovative
features, based on documented efﬁcacy and a favourable
cost/beneﬁt ratio. For kyphoplasty, efﬁcacy data were collected
from published literature. Cost information was computed
taking into account: the cost of the device, the personnel, the
operating room, length of stay, from the hospital perspective.
RESULTS: At the time of the evaluation, published evidence
describing the efﬁcacy of kyphoplasty consisted mostly of uncon-
trolled retrospective studies. Regarding cost, the overall cost of
the procedure was calculated as follows: device €2250, medical
and nursing staff €486, health materials and operating room
€185, length of stay €2600, for a total of €5521. The DRG reim-
bursement associated with the use of kyphoplasty with no com-
plications is €4200, which does not cover the overall cost of 
the procedure. CONCLUSIONS: Despite poor clinical data and
unfavourable economic analysis, the MDFC approved the use of
kyphoplasty only for 10 selected patients per year, requiring the
physician to report the outcomes of the treated patients, in order
to re-evaluate the use in the future.
PHP29
REIMBURSEMENT OF HIGH-PRICED NEW EMERGING
MEDICAL TECHNOLOGIES IN A DRG-BASED HOSPITAL 
CARE SYSTEM
Hessel FP, Greß S,Wasem J
University of Duisburg-Essen, Essen, NRW, Germany
Newly developed, already licensed, high-priced medical devices
for critically ill patients impose additional costs especially on the
hospital sector. In countries with a DRG-based reimbursement
system there are no economic incentives for hospitals to use the
new technologies as long as the additional costs are not com-
pensated. OBJECTIVES: The objective of this paper is to analyse
the structures of the German health care system which are
involved in the implementation of new high-priced medical tech-
nologies the hospital sector in the reimbursement system and 
to determine key factors of a successful implementation.
METHODS: The institutions involved in the determination of
the catalogue of reimbursed items based on the just newly intro-
duced German DRG-system are described and examined. Illus-
trated by examples the launching of newly emerging medical
devices for inpatient treatment is analysed. Investigated parame-
ters were the number and quality of studies published, the
